CVS Health's pharmacy benefit manager unit must pay the U.S. government $95 million after a federal judge found it ...

CVS must pay the government at least $95 million after a federal court ruled in favor of a whistleblower, finding its pharmacy benefit subsidiary Caremark overcharged Medicare for generic drugs.

The contract, though sizable, is likely immaterial to CVS’ earnings. But it moves the company in a positive direction as it ...

Rising prescription drug costs remain a top healthcare concern, with pharmacy benefit managers (PBMs) facing heightened scrutiny for their role in managing prescription drug benefits for insurers and ...

The California Public Employees’ Retirement System (CalPERS) has a new pharmacy benefits contract with CVS Caremark, the ...

CVS stock surges nearly 50% in 2025, aided by strong Q1 results, raised guidance and easing Medicare regulation risks.

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

CVS Caremark has been ordered to pay $95 million after a federal judge found the pharmacy benefit manager improperly inflated Medicare Part D drug prices by failing to report required pharmacy ...

CVS Caremark is striving to acquire a leading position in the Medicare Prescription Drug Plan business in the U.S. It aggressively grew its Pharmacy Benefits Management business in 2011, winning ...

CVS Caremark has removed coverage of Zepbound, a GLP-1 weight-loss drug, citing pricing concerns and shifting payer dynamics ...

CVS must pay the government at least $95 million after a federal court ruled in favor of a whistleblower, finding its pharmacy benefit subsidiary Caremark overcharged Medicare for generic drugs.